Clinical Trials - April 20, 2016
BioInvent’s BI-505 study ready to start
BioInvent International has announced that patient recruitment into the trial can now start in the upcoming clinical Phase II study with the antibody BI-505 in patients with multiple myeloma, as necessary regulatory approvals have been obtained. Multiple myeloma is a bone marrow cancer which affects more than 120,000 people globally every year. Initial treatment is often […]